Immunex Q1 net income rises 24 pct
WEDNESDAY, APRIL 18, 2001 4:42 PM
- Reuters
SEATTLE, April 18 (Reuters) - Drug maker Immunex Corp. (NASDAQ NM:IMNX)
said Wednesday its first quarter profits rose 24 percent, just above Wall Street
forecasts, as sales of its flagship anti-arthritis treatment Enbrel rose 26 percent.
The Seattle-based company said net income for the quarter reached $39.8 million,
or 7 cents a share, up from $32.2 million, or 6 cents a share, in the same period a
year ago.
Analysts polled by First Call/Thomson Financial had on average estimated
quarterly profit at 6 cents a share, with projections ranging between 4 cents and 8
cents.
Immunex said total revenues for the quarter rose to $217.8 million from $179.0
million in the first quarter of 2000.
Enbrel sales rose to $164.9 million in the latest quarter, a gain of 26 percent over
the same period in 2000.
REUTERS
Rtr 16:42 04-18-01
Selector Code: reuco
Copyright 2001, Reuters News Service
Gruß
ernu... wieder
WEDNESDAY, APRIL 18, 2001 4:42 PM
- Reuters
SEATTLE, April 18 (Reuters) - Drug maker Immunex Corp. (NASDAQ NM:IMNX)
said Wednesday its first quarter profits rose 24 percent, just above Wall Street
forecasts, as sales of its flagship anti-arthritis treatment Enbrel rose 26 percent.
The Seattle-based company said net income for the quarter reached $39.8 million,
or 7 cents a share, up from $32.2 million, or 6 cents a share, in the same period a
year ago.
Analysts polled by First Call/Thomson Financial had on average estimated
quarterly profit at 6 cents a share, with projections ranging between 4 cents and 8
cents.
Immunex said total revenues for the quarter rose to $217.8 million from $179.0
million in the first quarter of 2000.
Enbrel sales rose to $164.9 million in the latest quarter, a gain of 26 percent over
the same period in 2000.
REUTERS
Rtr 16:42 04-18-01
Selector Code: reuco
Copyright 2001, Reuters News Service
Gruß
ernu... wieder
